Forekomsten af hjertesvigt var 2, 4% ved kombinationbehandling med insulin (rosiglitazon givet for at understøtte insulinbehandling), sammenlignet med 1, 1% ved behandling med insulin alene.
The incidence of heart failure in combination with insulin (rosiglitazone added to established insulin therapy) was 2.4%, compared to insulin alone, 1.1%.